A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Dermira, Inc..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
377actual
Sites
85
Countries
Argentina, Australia, Brazil +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-18 | actual | When the study began enrolling |
| Primary completion | 2026-01-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Eczema
Interventions
- Drug: Lebrikizumab — also filed as LY3650150, DRM06
- Drug: Placebo
- Drug: Topical Corticosteroid (TCS)
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline
measured Baseline to Week 16
Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score
measured Baseline to Week 16
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed